Recent Updates
Recently added Catalysts
REPL Negative Sentiment Score: 20/100

REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Replimune Group, Inc. Investors of Upcoming Deadline

Key Takeaway: Replimune Group, Inc. is under a securities fraud class action lawsuit filed in the U.S. District Court for the District of Massachusetts. The lawsuit alleges that the company and its senior officers made misrepresentations about the IGNYTE trial for their lead drug candidate, RP1, intended for treating advanced melanoma. Investors who purchased shares from November 22, 2024, to July 21, 2025, may be affected and need to file as lead plaintiffs by September 22, 2025, if they wish to participate in the legal proceedings.

Market Sentiment Analysis

CONCERNS & RISKS

  • Replimune Group, Inc. is facing a securities fraud class action lawsuit.
  • Allegations involve misrepresentations regarding the IGNYTE trial's prospects for RP1.
  • Investors who acquired shares between specific dates may have lost money.

Full Press Release Details

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Should You Join This Class Action Lawsuit?
Do you, or did you, own shares of Replimune Group, Inc. (NASDAQ: REPL)?
Did you purchase your shares between November 22, 2024, and July 21, 2025, inclusive?
Did you lose money in your investment in Replimune Group, Inc.?
If you purchased or acquired Replimune securities, and/or would like to discuss your legal rights and options please visit Replimune Group, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
A lawsuit was filed in the United States District Court for the District of Massachusetts on behalf of investors who purchased or acquired the securities of Replimune between November 22, 2024, and July 21, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.
Replimune’s lead drug product candidate is RP1, a cancer drug. According to the lawsuit, Defendants made misrepresentations concerning the IGNYTE trial’s prospects for RP1 in combination with nivolumab for the treatment of advanced melanoma.
If you wish to serve as lead plaintiff for the Class, you must file papers by September 22, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

replimune class action

Frequently Asked Questions

What is the Replimune class action about?

The class action alleges securities fraud related to Replimune's drug RP1 and its trials.

Who can join the Replimune class action lawsuit?

Investors who purchased Replimune shares between November 22, 2024, and July 21, 2025.

What is the deadline to file as lead plaintiff?

The deadline to file as lead plaintiff is September 22, 2025.

How are legal fees handled in this class action?

All representation is on a contingency fee basis; shareholders pay no fees.

Who can I contact for more information?

Contact Investor Relations Manager Peter Allocco at (212) 951-2030 or via email.

Last updated: Sep 2, 2025